Kornimate/medical-research-clean huggingface dataset:
repetitive transcranial magnetic stimulation trajectory of outcomes study

Conditions: Depressive Disorder

Summary: this prospective, single-arm, open-label feasibility study will assess the safety, tolerability, and effectiveness of repetitive transcranial magnetic stimulation (rtms) in patients with major depression (mdd) to test the hypothesis that remission rates can be increased by additional treatment sessions.


Eligibility criteria:
inclusion criteria: * are outpatients * are voluntary and competent to consent to treatment * are between the ages of 18 and 85, inclusive * are able to adhere to the treatment schedule * pass the tms safety-screening questionnaire * have had no change or initiation of any psychotropic medication in the 4 weeks prior to screening exclusion criteria: * previous rtms treatment * have a history of substance dependence or abuse within the last 3 months * have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump * have active suicidal intent * have a diagnosis of any personality disorder, and assessed by a study investigator to be primary and causing greater impairment than mdd * have a diagnosis of any psychotic disorder * have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure confirmed diagnostically by neurological assessment (except those therapeutically induced by ect), cerebral aneurysm, parkinson's disease, huntington's chorea, dementia, stroke, neurologically confirmed diagnosis of traumatic brain injury, or multiple sclerosis. * if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study * clinically significant laboratory abnormality, in the opinion of the investigator * currently (or in the last 4 weeks) take more than lorazepam 4 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rtms efficacy * non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview) * any significant cardiovascular or metabolic disorder or insult including, but not limited to: coronary artery disease, abnormal heart rhythms, heart failure, cardiac valve disease, congenital heart disease, cardiomyopathy, vascular disease, dyslipidemia, diabetes, or hypertension

Keywords: rtms tms repetitive transcranial magnetic stimulation major depressive disorder major depression mdd
the mechanical,physiological and therapeutic effects of eccentric exercise combined with extracorporeal shockwave therapy in athletes with patellar tendinopathy

Conditions: Patellar Tendinopathy

Summary: patellar tendinopathy is one of the most common injuries in jumping athletes. changes in mechanical and physiological properties of tendon are the two proposed forms of pathogenesis. the efficacy of eccentric exercise when applied alone and combined with extrocoporeal shockwave therapy had been reported; however, the underlying treatment mechanisms of pain and dysfunction are not clear. this project aimed to explore the mechanical, physiological and therapeutic effects of eccentric exercise when applied as a single treatment and as an adjunct to extracorporeal shockwave therapy.


Eligibility criteria:
inclusion criteria: * competitive athletes * pain at the inferior pole of the patella with training for at least 3 months * tenderness at the inferior pole of the patella on palpation exclusion criteria: * patellofemoral pain syndrome, fat pad irritations, meniscus injury, osteoarthritis, rheumatoid arthritis or infections * history of fracture over lower limbs and inflammatory myopathies * cortisone injuection and other interventions within 3 months * contraindication to extracorporeal shockwave therapy
mimics-3d-usa registry study

Conditions: Peripheral Arterial Disease

Summary: the mimics-3d-usa study is a prospective, multicentre, observational study (non-investigational) of the biomimics 3d vascular stent system that evaluates evaluate safety, effectiveness and device performance within a real-world clinical population of patients undergoing femoropopliteal intervention for the treatment of peripheral artery disease.

the mimics-3d-usa study is designed to enable the collection, analysis, reporting and presentation of data from use of the biomimics 3d vascular stent system purchased by the hospital / institution or office interventional suite and used in accordance with the ifu associated with the product's fda approval. the intent of this post-market observational study is to increase the understanding of the performance of the biomimics 3d vascular stent system in a larger population of patients representative of a real-world situation within us hospitals, institutions and office-based interventional suites or labs.

Eligibility criteria:
inclusion criteria: * patient is age ≥18 and ≤85 years at the date of consent. * patient has provided written informed consent for participation in the study prior to index procedure. * patient has documented symptomatic peripheral arterial disease scheduled for treatment with the biomimics 3d vascular stent system in accordance with the ifu. exclusion criteria: * patients whose lesions cannot be crossed with a wire and/or balloon catheter and cannot be dilated sufficiently to allow passage of the delivery system. * patients with a history of intolerance or adverse reaction to antiplatelet and/or anticoagulation therapies, bleeding diathesis or severe hypertension. * patients with known hypersensitivity to nickel-titanium. * patient has a comorbidity that in the investigator's opinion would limit life expectancy to less than 12 months. * patient is pregnant or breastfeeding. * patient is unable or is unwilling to comply with site standard of care procedures

Keywords: pad pvd sfa stent stent helical stent vascular stent
study of mk0476 (montelukast sodium) and effects on asthma and nasal symptoms upon exposure to cats (0476-256)

Conditions: Asthma, Bronchial; Rhinitis, Allergic, Perennial

Summary: the purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.

the duration of treatment is 2 weeks.

Eligibility criteria:
inclusion criteria: * increased sensitivity to cat allergen proven by positive allergy testing, and by decreased lung function and increased symptoms of allergic rhinitis (runny nose) upon exposure to cats. exclusion criteria: * medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.

Keywords: rhinitis, allergic
weight loss and cognitive function in adults

Conditions: Overweight and Obesity

Summary: more than two-thirds of middle-aged and older adults are overweight, which places them at greater risk of disability and higher medical expenses. lifestyle interventions which promote weight loss for this population are needed. however, it is not known how different weight loss approaches impact brain (cognitive) functions, such as memory and attention. the investigator's investigation aims to improve adherence to a hypocaloric diet prescription through improved attention and inhibitory control, reduced hunger, and increased satiety. the objectives of this pilot study are to: 1) determine the feasibility and establish proof-of-concept; 2) establish proficiency and feasibility of the proposed cognitive function assessments; and 3) obtain preliminary data for effect size generation.


Eligibility criteria:
inclusion criteria: * overweight or obese, bmi 25-40 kg/m\^2 * able to use a computer, keyboard, and mouse exclusion criteria: * uncontrolled hypertension * orthopedic injury * other conditions that preclude participation in a walking program * previous participation in psychology research which involved computerized cognitive testing * diabetes which requires insulin

Keywords: weight loss cognitive function weight maintenance
intensive insulin therapy for strict glycemic control in neurosurgical patients: safety and efficacy

Conditions: Subarachnoid Hemorrhage; Traumatic Brain Injury; Intracranial Hemorrhage

Summary: strict glycemic control improves mortality and morbidity of patients admitted to the postoperative intensive care unit (icu). the investigators would like to know if this therapy could improve the long term neurologic and cognitive outcomes of patients treated for acute subarachnoid hemorrhage with either a surgical or intravascular approach.

intensive insulin therapy and strict glycemic control (80-120 mg/dl) versus standard insulin therapy in neurosurgical intensive care patients (subarachnoid hemorrhage, traumatic brain injury, intracranial expanding lesion): safety, and efficacy (mortality, morbidity, long term neurologic outcome).

Eligibility criteria:
inclusion criteria: * subarachnoid hemorrhage * traumatic brain injury * intracranial hemorrhage

Keywords: neurointensive care intensive insulin infusion hypoglycemia postoperative mortality postoperative morbidity neurologic outcome
supportive programs for supporting optimal recovery in participants undergoing gynecological surgery

Conditions: Ovarian Neoplasm; Uterine Neoplasm

Summary: this trial studies how well two different supportive programs work in supporting optimal recovery in participants undergoing gynecological surgery. supportive programs use different methods for helping participants cope with the surgical experience including gentle movements, counseling, writing, or relaxation techniques, and may help improve participants' well-being after gynecological surgery.

primary objectives: i. to calculate recruitment, adherence, assessment completion, and retention rates. secondary objectives: i. document the frequency of adverse events. ii. assess descriptive data on proposed outcomes (i.e., pain, sleep disturbances, psychological distress) for the next phase of study.) iii. qualitatively assess acceptability to guide future study planning. outline: participants are randomized to 1 of 2 groups. group i (mindful movement and breathing \[emmb\]): participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. this will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery. group ii (attention control \[ac\]): participants will receive caring attention. this will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.

Eligibility criteria:
inclusion criteria: * scheduled for an abdominal gynecological surgery (i.e. uterine, ovarian) to remove a suspected malignancy. * have an eastern cooperative oncology group (ecog) performance status of =\< 1. * cognitively able to complete assessments as judged by the study team. * able to understand, read and write english. exclusion criteria: * have schizophrenia or any other psychotic disorder. * have a diagnosed sleep disorder including untreated obstructive sleep apnea, periodic limb movement disorder, or restless leg syndrome.
becoming a parent during the covid-19 pandemic in austria and germany

Conditions: Parents; COVID-19 Pandemic

Summary: this is an online survey in austria and germany directed at parents with children born since the start of the first lockdown of the covid-19 pandemic (birthdate beginning with 16.03.2020). the survey includes questions about: * current stress levels and depressive symptoms, * resilience during the pandemic, * social support, * retrospective birth risk factors, pregnancy distress and pregnancy experience, * demographic factors and * other questions related to parenting and the covid-19 pandemic.

the study evaluated data collected in the course of an online survey during the covid-19 pandemic in austria and germany. the questions were conceived to reflect aspects of pregnancy, childbirth and early child rearing that could be affected by the pandemic, and included commonly used and previously validated scores for assessing pregnancy distress (pregnancy distress questionnaire, pdq), birth experiences (childbirth experience questionnaire 2, ceq2) postnatal depression (edinburgh postnatal depression scale, epds), perceived stress (perceived stress scale, pss) and pandemic-related experiences (pandemic resilience part, adapted to postnatal period, from the pandemic related stress in pregnancy scale, preps). in addition, the investigators composed questions and scales that referred to specific pandemic- and parenting-related issues that were not covered otherwise. the investigators also tried to question both the fathers and the mothers, and consequently mothers received more pregnancy-related questions than fathers. furthermore, biological mothers received childbirth-related questions which were omitted for adoptive mothers.

Eligibility criteria:
inclusion criteria: * parents that had a baby born since the 16th of march 2020 (which corresponds to the beginning of the first lockdown in austria and in bavaria, germany) * living in austria or germany exclusion criteria: * stillborn or neonatal death
study of t cell phenotype activation pathway in human alcoholic liver disease

Conditions: Alcoholic Liver Disease; Chronic Hepatitis C Virus

Summary: alcoholic liver disease is characterized by circulating t cell activation and liver t cell infiltration but their phenotype is poorly studied. the aim of the study is to test the hypothesis that the (cd4+ t cell secreting interleukin-17) th17 pathway is involved in alcoholic liver disease.

consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis c virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver t cell infiltrates.

Eligibility criteria:
inclusion criteria: * alcohol excess intake and suspected liver disease * alcohol excess intake and clinical liver cirrhosis * chronic hepatitis c virus infection and suspected liver disease * chronic hepatitis c virus infection and clinical liver cirrhosis exclusion criteria: * bacterial or fungal infection * immunosuppressive treatment * other causes of liver disease

Keywords: liver alcohol lymphocyte
tomotherapy in locally advanced gallbladder and pancreatic cancers

Conditions: Pancreatic Neoplasms Malignant; Malignant Neoplasm of Gall Bladder Non-resectable

Summary: summary project title: concurrent chemo-radiation using tomotherapy based imrt in locally advanced gallbladder and pancreatic cancers: a phase ii study specific objectives: primary to assess the radiological response by dose escalated imrt in locally advanced inoperable gallbladder and pancreatic cancers. secondary 1. to assess the resectability rate with microscopic negative margin (r0). 2. to assess the acute and late toxicities (number of participants with adverse events as a measure of safety and tolerability) 3. to study the locoregional control in the patients undergoing r0 resection 4. to study overall survival design: phase ii study study population: all patients of age \>18 years years diagnosed with non metastatic locally advanced inoperable gall bladder and pancreatic cancer study size: 60 patients methodology: sixty cases will be screened and taken for study if eligible after taking the informed consent. patients will receive radiotherapy using tomotherapy based imrt with concurrent chemotherapy gemcitabine weekly. the response will evaluated at 6 weeks post chemoradiation and if operable will undergo surgery, if still inoperable or metastatic will receive palliative chemotherapy. project period: total project period : 3 years recruitment, data collection : 2 years complete analysis of data : 1 year study site: tata memorial centre

in both gall bladder and pancreatic cancer surgery is the main stay of treatment, but majority of these tumors are inoperable by virtue of adjacent organ infiltration. in this study, inoperable gallbladder and pancreatic cancer patients will be treated with high precision radiotherapy using tomotherapy delivering higher dose of radiation along with chemotherapy. it is expected that this high dose precise radiotherapy along with chemotherapy will lead to good symptom relief and make some of these tumors operable.

Eligibility criteria:
inclusion criteria: 1. inoperable locally advanced gall bladder and pancreatic cancer by virtue of vascular encasement of superior mesenteric artery (sma), celiac artery, hepatic artery, portal vein (pv) or deep hilar invasion precluding r0 resection. 2. biopsy proven adenocarcinoma 3. kps \>= 70 4. age \>18 years 5. medically fit for chemotherapy 6. normal hematological, renal and hepatic function (serum bilirubin\<3mg/dl) 7. no prior history of treatment with radiation or chemotherapy. 8. patient willing and reliable for follow-up. exclusion criteria 1. any other malignancy in any site. 2. expected survival \< 3months. 3. severe co-morbid conditions ( severe cardiac disorder, severe bronchial asthma, severely compromised liver function, psychological disorder) 4. malignant ascitis. 5. distant metastases by clinical examination or by imaging/whole bodypet scan.

Keywords: gall bladder pancreatic cancers tomotherapy
the effect of systemic dietary instruction on management of plasma phosphorus levels in peritoneal dialysis (pd) patients

Conditions: Hyperphosphatemia

Summary: hyperphosphatemia is highly prevalent in pd patients, and it is an independent risk factor for all-cause and cardiovascular mortality in these patients. effective treatments are limited in suppressing plasma phosphorous. because of the nearly linear relationship between protein and phosphorus intake, high dietary protein intake (dpi, 1.2-1.3g/kg/d recommended by kdoqi) would load high phosphorus burden in pd patients. it is suggested that hyperphosphatemia is hard to avoid under such a dpi level, even as the patients take sufficient phosphorus blinders and receive high pd dosage. the present study is to investigate whether systemic dietary instruction would show effects on control of hyperphosphatemia in pd patients.


Eligibility criteria:
inclusion criteria: 1. stable on pd for at least three month 2. aged from 18 to 75 years old 3. informed consent approval exclusion criteria: 1. malnutrition (based on sga results) 2. infection or inflammation within 1 month 3. concurrent wasting disease (i.e. cancer, tuberculosis)
immunological mechanisms in sarcoidosis

Conditions: Sarcoidosis

Summary: there is no cure for the inflammatory disease sarcoidosis. virtually any part of the body can be affected but most often the lungs and lymph nodes. outcomes after diagnosis vary widely among sarcoidosis patients, with some experiencing resolving disease and others developing chronic disease and lung fibrosis. cardiac sarcoidosis can lead to life threatening arrythmias and calcium metabolism disturbances can lead to renal impairment. treatment with different forms of immunosuppressants are usually tried to dampen symptoms but are not effective in all patients. furthermore, the disease usually flares up after cessation of treatment. the variability in diseae course and treatment response is thought, at least to some degree, to be explained by individual differences in genetics, immune cells and signaling pathways. but existing evidence is limited. in other inflammatory diseases the gut microbiome is of importance for disease course but its role in sarcoidosis has not been clarified. in this prospective project the investigators will study genes, inflammatory cells and signaling molecules in the lung, upper airways and blood, and to some extent microbes, also in faeces. healthy volunteers will be included for comparative studies. most samples will be taken during normal diagnostic work-up and follow-up of patients with/with suspected sarcoidosis. the findings will be correlated to disease course and effects of different treatments. by linking to national health data and demographic registries, comorbidities and environmental factors will be correlated to data. by this, the investigators hope to improve understanding of which genes, cells and signaling molecules that are of importance for resolving vs non-resolving disease and why some patients respond to a certain treatment and others don´t. the overall goal is to assess and predict sarcoidosis outcomes. we hypothesize that blood-based biomarkers including those taken during routine care as well as novel cell, signaling molecules and genetic markers, in combination with clinical characteristics can be used to predict outcomes, also treatment response, in sarcoidosis. the results can lead to tailored treatment and individual follow-up for each patient with sarcoidosis.


Eligibility criteria:
inclusion criteria: * suspicion of sarcoidosis * swedish speaking * able to understand and approve of study protocol * no contraindications for planned interventions * for inclusion of healthy controls they need to be healthy and the same criteria as listed above for patients. exclusion criteria: * no suspicion of sarcoidosis * not swedish-speaking * not able to understand study protocol * not approving of study protocol * contraindications for planned interventions
therapeutic strategy associated with bdmards or tsdmards in rheumatoid arthritis and psoriatic arthritis

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis

Summary: this is a longitudinal, observational, prospective, multicentre study conducted in france, among a representative sample of rheumatology doctors. the aim of this study is to describe in real life the therapeutic strategy when faced with a patient with rheumatoid arthritis (ra) or psoriatic arthritis (psa) who requires initiation of treatment with biotherapy or targeted therapy. the evolution of the disease and the possible therapeutic adaptations will then be followed for 2 years.


Eligibility criteria:
inclusion criteria: * major patient (age ≥ 18 years) * patient with ra according to american college of rheumatology (acr) / european congress of rheumatology (eular) 2010 or acr 1987 or patient with psa according to classification criteria for psoriatic arthritis (caspar) criteria * patient undergoing treatment with methotrexate (mtx) (oral or injectable) initiated for at least 3 months. * naïve patient of biotherapy or tsdmard and requiring the introduction of a first bdmard or tsdmard due to the activity of the disease. * patient informed and accepting the computer processing of his/her medical data and informed of his/her rights of access and rectification. exclusion criteria: * patient participating in an interventional study in rheumatology * patient with axial spondyloarthritis (for patients with psa)
remicade infusion management program

Conditions: Crohn Disease; Arthritis, Rheumatoid

Summary: janssen inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. it is expected that about 12 sites from the remicade infusion network (r.i.n.) will participate. this registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.


Eligibility criteria:
inclusion criteria: * subject is a good candidate to receive infliximab as per the product monograph * subject is prescribed infliximab by an appropriate physician * subject receives infusion in a community infusion centre. * subject has signed the approved consent form. exclusion criteria: * not specified in the protocol

Keywords: crohn's disease, rheumatoid arthritis